Get the Stockscreener App
2.78
5.44%
-0.16
Pre-market:
2.69
-0.09
-3.24%
Imunon Inc stock is traded at $2.78, with a volume of 3.50M.
It is down -5.44% in the last 24 hours and down -12.03% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$2.94
Open:
$2.6
24h Volume:
3.50M
Relative Volume:
36.27
Market Cap:
$9.45M
Revenue:
$125.00K
Net Income/Loss:
$-14.33M
P/E Ratio:
-0.3993
EPS:
-6.9622
Net Cash Flow:
$-14.95M
1W Performance:
-6.40%
1M Performance:
-12.03%
6M Performance:
-46.44%
1Y Performance:
-78.68%
1-Day Range:
$2.52
$2.93
1-Week Range:
$2.52
$3.08
52-Week Range:
$2.52
$41.22
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
2.78 | 9.45M | 125.00K | -14.33M | -14.95M | -6.9622 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Imunon Inc Stock (IMNN) Latest News
Imunon Inc. Expands Market Footprint Amid Strategic Deals and Financial Challenges - timothysykes.com
IMUNON's IMNN-001 Shows Continued Gains In Overall Survival In Phase 2 Ovarian Cancer Trial - RTTNews
Imunon (IMNN) Reports Promising Phase 2 OVATION 2 Trial Results - GuruFocus
IMUNON reports improved survival data for ovarian cancer therapy By Investing.com - Investing.com UK
IMUNON Reports Updated Phase 2 Data Showing Continued - GlobeNewswire
Guidance Update: Can Imunon Inc reach all time highs this yearJobs Report & Safe Capital Investment Plans - baoquankhu1.vn
Aug Closing: Is Imunon Inc stock a good pick for beginners2026 Big Picture & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - marketscreener.com
IMUNON to outline 2025 results and IMNN-001 update March 31 - Stock Titan
IMUNON, Inc. Files Form 8-K with NASDAQ Listing and Company Details for March 2026 - Minichart
Imunon Expands At-The-Market Equity Offering Capacity - TipRanks
Imunon registers additional $7 million in shares under at-the-market offering - Investing.com
Imunon registers additional $7M, raising ATM capacity to $17M - TradingView
Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M - Stock Titan
Imunon (NASDAQ: IMNN) ups ATM program by $7M to $17M capacity - Stock Titan
S P Trends: What is the next catalyst for Imunon Inc2026 Weekly Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Dividend Watch: Will Imunon Inc outperform tech stocksQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Imunon Q2 2025 Earnings Preview - MSN
Imunon declares $0.15 dividend - MSN
Signal Recap: Will Imunon Inc outperform tech stocksGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Market Overview: Is Imunon Inc a defensive stock2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
IMNN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
IMNN SEC FilingsImunon Inc 10-K, 10-Q, 8-K Forms - Stock Titan
IMNN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Imunon Inc expected to post a loss of $1.17 a shareEarnings Preview - TradingView
What risks investors should watch in Imunon Inc. stockWeekly Profit Report & Risk Controlled Swing Alerts - mfd.ru
Can Imunon Inc continue delivering strong returnsJuly 2025 Chart Watch & Reliable Breakout Forecasts - baoquankhu1.vn
Armistice Capital takes 9.99% stake in Imunon (IMNN) - Stock Titan
Will Imunon Inc. outperform small cap indexesWeekly Risk Report & Free Community Supported Trade Ideas - mfd.ru
Will Imunon Inc. outperform tech stocksQuarterly Trade Report & Technical Entry and Exit Alerts - mfd.ru
Should I invest in Imunon Inc. before earningsIPO Watch & Consistent Profit Trade Alerts - mfd.ru
FY2025 Earnings Estimate for Imunon Issued By HC Wainwright - Defense World
Imunon stock price target raised to $25 from $14 at H.C. Wainwright By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN) - The Globe and Mail
IMNN: Streamlining Operations to Focus on OVATION 3 - Smartkarma
Rate Hike: Will Imunon Inc outperform its industry peersJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Imunon stock price target raised to $25 from $14 at H.C. Wainwright - Investing.com Australia
Imunon, Inc. Announces Retirement of Executive Vice President and Chief Scientific Officer Khursheed Anwer, Effective February 20, 2026 - marketscreener.com
Imunon sharpens focus on its promising pivotal Phase 3 ovarian cancer study - marketscreener.com
IMUNON rises on plan to shift resources to ovarian cancer therapy - TradingView
Imunon stock rises following strategic restructuring to focus on Phase 3 trial - Investing.com Nigeria
Imunon stock rises following strategic restructuring to focus on Phase 3 trial By Investing.com - Investing.com South Africa
Imunon announces orderly retirement of chief scientific officer - TipRanks
IMUNON, Inc. Announces Strategic Restructuring and Retirement of Chief Scientific Officer to Advance Phase 3 Clinical Trial - Quiver Quantitative
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - One News Page
Resistance Check: Is MLTX stock a buy or sellGold Moves & Safe Entry Momentum Tips - baoquankhu1.vn
Stock Analysis: Can Imunon Inc sustain earnings growthTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
Imunon CEO says ‘poised for key milestones’ as company enters 2026 - MSN
Pullback Watch: Can Imunon Inc continue delivering strong returnsQuarterly Earnings Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Mood: What is Franklin BSP Realty Trust Incs debt to equity ratioPortfolio Gains Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Is Imunon Inc. stock a good pick for beginnersQuarterly Earnings Summary & Verified Momentum Watchlists - bollywoodhelpline.com
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):